Genus plc (GENSY)
| Market Cap | 2.30B +42.4% |
| Revenue (ttm) | 904.44M +0.1% |
| Net Income | 63.93M |
| EPS | 0.95 |
| Shares Out | n/a |
| PE Ratio | 35.96 |
| Forward PE | 24.83 |
| Dividend | 0.36 (1.02%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 147 |
| Average Volume | 916 |
| Open | 34.92 |
| Previous Close | 35.31 |
| Day's Range | 34.92 - 34.92 |
| 52-Week Range | 24.34 - 44.14 |
| Beta | 0.94 |
| RSI | 44.91 |
| Earnings Date | Sep 10, 2026 |
About Genus
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as technical services and advice under the PIC brand. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom. [Read more]
Financial Performance
In fiscal year 2025, Genus's revenue was 672.80 million, an increase of 0.60% compared to the previous year's 668.80 million. Earnings were 19.30 million, an increase of 144.30%.
Financial numbers in GBP Financial StatementsNews
Genus Power Surpasses 26 Million Smart Meter Deployment Worldwide, Reinforcing Leadership in End-to-End Advanced Metering Solutions
JAIPUR, India, March 2, 2026 /PRNewswire/ -- Genus Power (NSE: GENUSPOWER) (BSE: 530343), India's leading end-to-end energy measurement and advanced metering solutions provider, has crossed a signific...
UK animal genetics firm Genus surges on annual profit forecast upgrade
British animal genetics company Genus expects to report full-year adjusted pretax profit "moderately above" the upper end of current market expectations, sending its shares as much as 15.3% higher on ...
British animal genetics firm Genus surges on strong annual profit growth
Shares of British animal genetics firm Genus shot up nearly 29% on Thursday, after it reported a 38% surge in annual adjusted pretax profit, on a constant currency basis.
UK's Genus secures FDA approval for PRP gene edit; shares soar
British animal genetics company Genus on Wednesday said the U.S. Food and Drug Administration (FDA) approved its PRP gene edit under its PRRS Resistant Pig ("PRP") programme for use in the U.S. food s...